Anti-Smoking Drug Linked to Heart Risks

A study found that Pfizer’s anti-smoking drug Chantix poses significant cardiovascular risks, a claim the pharmaceutical giant immediately denied while defending the drug’s benefits. The study, published in the Canadian Medical Association Journal, showed Chantix is linked to a 72 percent greater risk of hospitalization due to a serious adverse cardiovascular event like a heart attack or arrhythmia.


“We have known for many years that Chantix is one of the most harmful prescription drugs on the US market.  It causes loss of consciousness, visual disturbances, suicides, violence, depression and worsening of diabetes…and now add CV risks.” study investigator.